Navigation Links
Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
Date:2/2/2009

ROCKVILLE, Md., Feb. 2 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Alternext US: CUR) announced today that Richard Garr, CEO and President, will present at the 11th Annual BIO CEO & Investor Conference to be held on February 9-10, 2009, at the Waldorf=Astoria Hotel, New York City.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO)

Neuralstem's presentation is scheduled for Monday, February 9, 2009 at 10:00 a.m. Eastern Time.

The presentation will be webcast live and will be available on the Investor Relations section of Neuralstem's website at www.neuralstem.com. For those who are not available to listen to the live broadcast, the call will be archived.

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS). The Company filed an IND (Investigational New Drug) application with the FDA for ALS clinical trials in December, 2008, and has entered into a collaborative agreement with Albert-Ludwigs-University, in Freiburg, Germany, to develop clinical trials for Huntington's disease.

In pre-clinical work, the company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
2. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
3. Neuralstem Reports Second Quarter Financial Results and Highlights
4. Neuralstem Fills Key Product Development Position
5. Neuralstem Responds to New StemCells, Inc. Lawsuit
6. Neuralstem Sues StemCells, Inc. Over New Patent
7. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
8. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
9. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
10. Neuralstem Shares Accepted for Trading on Amex(R)
11. The EntreTech Forum Presents... Greening Of America - The Conversion of Bio-Agriculture, Bio-Energy, and Bio-Products to Eco-Sustainable Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
Breaking Biology News(10 mins):